Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis

Published:2021-09-08 Issue: Volume: Page:ejhpharm-2021-002803
ISSN:2047-9956
Container-title:European Journal of Hospital Pharmacy
language:en
Short-container-title:Eur J Hosp Pharm

Author:

Shen Xiang,Huang Shangke,Xiao Hua,Zeng Shan,Liu Jiexing,Ran Zhuolan,Xiong Bin

Funder

Doctoral Startup Fund of the Affiliated Hospital of Southwest Medical University

Publisher

BMJ

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference53 articles.

1. Cancer treatment and survivorship statistics, 2019

2. Contribution of regulatory T cells to cancer: A review

3. Immune evasion in cancer: Mechanistic basis and therapeutic strategies

4. Unique roles of tryptophanyl-tRNA synthetase in immune control and its therapeutic implications

5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in the use of immune checkpoint inhibitors for non-small cell lung cancer in the Netherlands from 2016 to 2020, a national cancer registry analysis;2024-03-12

2. Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials;Expert Opinion on Investigational Drugs;2024-02-23

3. Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications;Frontiers in Oncology;2023-10-24

4. Smart Sensors and Microtechnologies in the Precision Medicine Approach against Lung Cancer;Pharmaceuticals;2023-07-22

5. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy;Journal of Thoracic Oncology;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3